The TRU-type is a lung adenocarcinoma with bronchial epithelial phenotype with initial oncogene mutations such as EGFR, KRAS, and MET amplification, HER2 amplification, and later a second mutation leading to the loss of the BRM protein causing a subsequent poorer differentiation of the tumor. This evidence concerns the gene KRAS and lung adenocarcinoma.